

Accepted Manuscript

Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies

Dean Quinn, Christopher N. Barnes, Wayne Yates, David L. Bourdet, Edmund J. Moran, Peter Potgieter, Andrew Nicholls, Brett Haumann, Dave Singh

PII: S1094-5539(17)30119-0

DOI: [10.1016/j.pupt.2017.10.003](https://doi.org/10.1016/j.pupt.2017.10.003)


Reference: YPUPT 1667

To appear in: *Pulmonary Pharmacology & Therapeutics*

Received Date: 5 May 2017

Revised Date: 29 September 2017

Accepted Date: 2 October 2017



Please cite this article as: Quinn D, Barnes CN, Yates W, Bourdet DL, Moran EJ, Potgieter P, Nicholls A, Haumann B, Singh D, Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies, *Pulmonary Pharmacology & Therapeutics* (2017), doi: 10.1016/j.pupt.2017.10.003.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): results of two randomized, double-blind, phase 2 studies

Dean Quinn^a, Christopher N Barnes^b, Wayne Yates^b, David L Bourdet^b, Edmund J Moran^b, Peter Potgieter^c, Andrew Nicholls^d, Brett Haumann^{*c} Dave Singh^e

^aP3 Research, 121 Adelaide Road, Mount Cook, Wellington, New Zealand
(dean@p3research.co.nz)

^bTheravance Biopharma US, Inc., South San Francisco, CA, United States
(cbarnes@theravance.com, wyates@theravance.com, dbourdet@theravance.com,
emoran@theravance.com)

^cTheravance Biopharma UK, Limited, London, United Kingdom (peterpotgieter2@aol.com;
bhaumann@theravance.com)

^dPharmaceutical Consulting, Burlingame, CA, United States (andrew.10.nicholls@gmail.com)

^eUniversity of Manchester, Medicines Evaluation Unit, University Hospital of South Manchester, NHS Foundation Trust, Manchester, United Kingdom (dsingh@meu.org.uk)

***Corresponding author:**

Brett Haumann
Theravance Biopharma UK Limited
90 Fetter Lane
London,
UK
EC4A 1EQ
Email: bhaumann@theravance.com
Tel: 650-808-3709

Key words

Bronchodilator, COPD, long-acting muscarinic antagonist, revefenacin, rapid onset, nebulized, once-daily, inhalation, anti-muscarinic

Download English Version:

<https://daneshyari.com/en/article/8537802>

Download Persian Version:

<https://daneshyari.com/article/8537802>

[Daneshyari.com](https://daneshyari.com)